title: Outcome of post-prostatectomy radiotherapy in one institution.
abstract: We present a retrospective study to evaluate the outcome of postoperative radiotherapy for biochemical or clinical recurrent prostate cancer. Twenty-six patients (median age 60 years) underwent radiotherapy after radical prostatectomy between January 1997 and January 2004. Seven patients received adjuvant radiotherapy and 19 received salvage radiotherapy. The median prostate-specific antigen at diagnosis was 8.6 (0.9-89) and most (23 patients) presented with T(3)N(0) disease. The median follow up was 19.5 months (5-84 months). All patients received a dose of 61.2 Gy at 1.8 Gy per fraction, 20 initially receiving 45 Gy to the lesser pelvis. The median dose to the bladder, rectum and left femoral head were 55.6, 57.5 and 33.8 Gy, respectively. All patients were managed radiotherapeutically by the first author. Twenty-four patients are alive. Two patients have died, one from oesophageal cancer and the second from metastatic prostate cancer. Two other patients also developed metastatic disease. Four asymptomatic patients with a rising prostate-specific antigen are under observation. None of the 26 patients has developed a local recurrence. Seven patients have developed grade 1 late bowel effects and three a grade 2 late effect. Eight patients suffer from grade 1 late genitourinary effects and two from grade 2 effects. One patient developed impotence, whereas 23 patients were rendered impotent postoperatively. There were no grade 3/4 late effects. Postoperative radiotherapy is well tolerated and provides effective local control.
authors.affiliation: Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia. mborg@adradcentre.com.au
authors.forename: M
authors.initials: M
authors.lastname: Borg
authors.forename: P
authors.initials: P
authors.lastname: Sutherland
authors.forename: A
authors.initials: A
authors.lastname: Stapleton
authors.forename: J
authors.initials: J
authors.lastname: Bolt
authors.forename: D
authors.initials: D
authors.lastname: Steele
authors.forename: B
authors.initials: B
authors.lastname: Landers
authors.forename: A
authors.initials: A
authors.lastname: Porter
authors.forename: S
authors.initials: S
authors.lastname: Buxton
authors.forename: C
authors.initials: C
authors.lastname: Heilbornn
authors.forename: H-Z
authors.initials: HZ
authors.lastname: Wong
mesh_terms: D000368:Aged; D001315:Australia; D004307:Dose-Response Relationship, Radiation; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D011182:Postoperative Care / Q000379:methods*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D011829:Radiation Dosage; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen